Clinical Trial

The Efficacy of Sequential RT After Triple Therapy for uHCC

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated July 4, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC). However, tumor drug resistance is still a major problem and many patients fail to achieve complete necrosis of the lesions after treatment. This study aimed to investigate the efficacy and safety of sequential radiotherapy after triple therapy in patients with uHCC to improve tumor response rate.
Trial Details
NCT Number NCT07052448
Lead Sponsor Fujian Provincial Hospital
Conditions Hepatocellular Carcinoma
Enrollment 35 participants
Start Date 2020-11-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-04